Cationic Magnetic Nanoparticles Activate Natural Killer Cells for the Treatment of Glioblastoma
Source abstract
Abstract
The blood-brain barrier (BBB) and the immunosuppressive microenvironment of glioblastoma (GBM) severely hinder the infiltration and activity of natural killer (NK) cells, thereby reducing their clinical efficacy in GBM treatment. To address this challenge, we introduced an engineered living material, HEFDS-NK cells, designed to enhance the penetration of NK cells across the BBB and improve their cytotoxicity against GBM. HEFDS comprises magnetic nanoparticles modified using cationic polyethylenimine (PEI), selenocysteine (Sec), and sodium hyaluronate (HA) and cocultured with NK cells to form HEFDS-NK cells. With the assistance of HA and magnet targeting, HEFDS-NK cells can effectively cross the BBB and localize at the GBM site. Moreover, PEI enhances the expression of C-X-C chemokine receptor type 4 (CXCR4) and C-C chemokine receptor type 4 (CCR4) on NK cells, thereby improving their recognition and cytotoxicity against GBM. Additionally, Sec boosts the immune activity of NK cells against GBM. Upon recognizing GBM, the activated HEFDS-NK cells produce Granzyme B, Perforin, and IFN-γ, ultimately achieving effective therapy for GBM. This study demonstrates an effective treatment of GBM while enhancing NK cell activity and their ability to penetrate the BBB, providing an innovative and high-precision therapeutic approach for GBM.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Immune Cell Function and Interaction · CAR-T cell therapy research · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Key Laboratory of Biomedical Polymers of Ministry of Education and Department of Chemistry, Wuhan University, Wuhan 430072, P. R. China
Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, P. R. China
Funding
Tongji Hospital · National Natural Science Foundation of China
References (41)
Show source-provided references
1. 10.1038/d41573-022-00095-110.1038/d41573-022-00095-1 ↗
2. 10.1126/science.abq699010.1126/science.abq6990 ↗
3. 10.1038/s41586-023-05707-310.1038/s41586-023-05707-3 ↗
4. 10.1515/mr-2023-000510.1515/mr-2023-0005 ↗
5. 10.1016/j.blre.2018.11.00210.1016/j.blre.2018.11.002 ↗
6. 10.1016/j.intimp.2022.10858710.1016/j.intimp.2022.108587 ↗
7. 10.3389/fimmu.2021.64008210.3389/fimmu.2021.640082 ↗
8. 10.1158/2159-8290.CD-20-055610.1158/2159-8290.CD-20-0556 ↗
9. 10.3389/fimmu.2018.0186910.3389/fimmu.2018.01869 ↗
10. 10.1016/j.cell.2020.02.02910.1016/j.cell.2020.02.029 ↗
11. 10.1038/s41586-023-06945-110.1038/s41586-023-06945-1 ↗
12. 10.1002/advs.20220251910.1002/advs.202202519 ↗
13. 10.1002/adma.20180439510.1002/adma.201804395 ↗
14. 10.1038/s41573-019-0052-110.1038/s41573-019-0052-1 ↗
15. Fares J. · 2021 · 47710.1016/B978-0-12-824375-6.00021-7 ↗
16. 10.1038/s41568-019-0205-x10.1038/s41568-019-0205-x ↗
17. 10.3390/ijms1910287910.3390/ijms19102879 ↗
18. 10.1038/s44222-022-00004-610.1038/s44222-022-00004-6 ↗
19. 10.1021/acsnano.3c1067410.1021/acsnano.3c10674 ↗
20. 10.1016/j.biomaterials.2023.12232010.1016/j.biomaterials.2023.122320 ↗
21. 10.1002/adma.20230177910.1002/adma.202301779 ↗
22. 10.1002/smll.20230261310.1002/smll.202302613 ↗
23. 10.1002/advs.20210545110.1002/advs.202105451 ↗
24. 10.1073/pnas.200257111710.1073/pnas.2002571117 ↗
25. 10.1001/jamaneurol.2017.312910.1001/jamaneurol.2017.3129 ↗
26. 10.3389/fimmu.2018.0292410.3389/fimmu.2018.02924 ↗
27. 10.1021/acsami.0c1635710.1021/acsami.0c16357 ↗
28. 10.1097/CJI.000000000000008210.1097/CJI.0000000000000082 ↗
29. 10.4049/jimmunol.164.8.404810.4049/jimmunol.164.8.4048 ↗
30. 10.1002/adma.20230496310.1002/adma.202304963 ↗
31. 10.1002/adma.20230582810.1002/adma.202305828 ↗
32. 10.1021/acs.chemrev.2c0051210.1021/acs.chemrev.2c00512 ↗
33. 10.1016/j.biomaterials.2019.11941810.1016/j.biomaterials.2019.119418 ↗
34. 10.1002/anie.20171299610.1002/anie.201712996 ↗
35. 10.1038/s41467-023-35957-810.1038/s41467-023-35957-8 ↗
36. 10.1002/adma.20230356710.1002/adma.202303567 ↗
37. 10.1002/adhm.20220314310.1002/adhm.202203143 ↗
38. 10.1126/scitranslmed.abb808610.1126/scitranslmed.abb8086 ↗
39. 10.1016/j.mattod.2022.07.01410.1016/j.mattod.2022.07.014 ↗
40. 10.1073/pnas.210750711810.1073/pnas.2107507118 ↗
41. 10.1158/0008-5472.CAN-21-003510.1158/0008-5472.CAN-21-0035 ↗